adhereUp GmbH

For a recurrent subscription fee, we offer an integrated service of data analytics that enables to very precisely capture when patients take their tabs. Patient non-adherence to drug treatment is a well-known problem in chronic diseases but also during new drug development. We first focus on selling our service to pharma companies or Clinical Research Organisations (CROs) and help them better monitor patient adherence when they develop new drugs, focusing on tab drugs. The cost of new drug development can amount MCHF 100. We estimate pharma companies can pay few dollars per month to improve patient compliance to a new tab drug treatment, to better measure drug efficacy, to avoid trial delay because of lost of follow-up and new patients recruitment.